ANCA (anti-PR3, anti-MPO)

EUROPLUS Granulocyte Mosaic 25

EUROPLUS Granulocyte Mosaic 25 (granuloc. (EOH), granuloc. (HCHO), PR3, MPO, GBM, HEp-2+ granuloc. (EOH)): pANCA
EUROPLUS Granulocyte Mosaic 25
  • Screening test for the detection of antibodies against granulocyte cytoplasm (ANCA).
  • Indications: Wegener‘s granulomatosis, various forms of glomerulonephritis, primary sclerosing cholangitis, ulcerative colitis, Crohn's disease.
  • Initial dilution: serum undiluted and 1 : 10 in parallel; conjugate class anti-human IgG, FITC-labelled.
  • Using ethanol-fixed granulocytes, antibodies against granulocyte cytoplasm can be detected. In this case, two fluorescence patterns have to be differentiated: a granular fluorescence which is distributed evenly over the entire cytoplasm, leaving the cell nuclei free (cytoplasmic type, cANCA) or a smooth fluorescence wrapped ribbon-like around the cell nuclei (perinuclear type, pANCA).
  • Antibodies against all relevant granulocyte antigens as well as against further, as yet unknown antigens are detected simultaneously (see table below).
  • The composite substrate HEp-2 cells + granulocytes allows differentiation between pANCA and anti-nuclear antibodies (ANA) which can easily be confused when using ethanol-fixed granu­lo­cytes. In the case of a positive ANA result all nuclei of the HEp-2 cells fluoresce, whereas in the case of pANCA (as well as cANCA) only the granulocytes fluoresce.
  • The EUROPLUS substrates PR3 and MPO as monospecific tests can confirm results from conventional granulocyte screening tests. Recombinant GBM EUROPLUS™ substrate also provides additional reliability for diagnosis. When fluorescence patters are unclear (e.g. unspecific fluorescence caused by other cytoplasmic antibodies) these substrates facilitate evaluation.
PatternTarget antigenAssociated diseases
cANCA Proteinase 3Wegener's granulomatosis
pANCA MyeloperoxidaseMicroscopic arteriitis, Churg-Strauss syndrome, polyarteriitis nodosa
pANCA ElastaseUlcerative colitis, Crohn's disease, primary sclerosing cholangitis, SLE
pANCA Cathepsin GUlcerative colitis, primary sclerosing cholangitis, Crohn's disease
pANCA LysozymeUlcerative colitis, primary sclerosing cholangitis, Crohn's disease
pANCA LactoferrinUlcerative colitis, primary sclerosing cholangitis, Crohn's disease, SLE, rheumatoid arthritis
c/pANCABPIPrimary sclerosing cholangitis, ulcerative colitis, Crohn's disease
pANCA UnknownColitis ulcerosa, Crohn's disease

ProductOrder number
EUROPLUS Granulocyte Mosaic 25FA 1201-25


Incubated ANCA Profile ELISA (antigens: proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G, BPI)
  • Differentiation of antibodies against granulocyte cytoplasm (ANCA).
  • Indications: Wegener‘s granulomatosis, various forms of glomerulonephritis, primary sclerosing cholangitis, ulcerative colitis, Crohn's disease.
  • Serum dilution 1 : 101; conjugate class anti-human IgG, POD-labelled.
  • 6 relevant anti-granulocyte antibodies can be detected simultaneously and monospecifically: autoantibodies against proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G, BPI.
  • 1-point calibration, semi-quantitative. Calibrator pool and serum sample on native antigens, purified by affinity chromatography.
  • Available individual ELISA (3-point calibration, quantitative): proteinase 3 (PR3-hn-hr: native/recombinant), myeloperoxidase (MPO)
ProductOrder number
ANCA Profile ELISA (IgG)EA 1200-1 G

Anti-PR3-hn-hr ELISA

The reagent wells of the Anti-PR3-hn-hr ELISA are coated with a mixture of recombinant PR3 (based on human cDNA expressed in human cells; Sun, Specks et al., 1998) and native PR3. The test shows a very high specificity (99%) at a much higher sensitivity (94%) than ELISAs based only on native antigen (88% or 78%; cooperative study with the ANCA reference centre at the University of Maastricht, Prof. Cohen-Tervaert). The significantly higher sensitivity of the Anti-PR3-hn-hr ELISA and its suitability for indicating relapses in patients on therapy has also been demonstrated in an independent publication (Damoiseaux et al. Ann Rheum. Dis. 2009, 68(2):228-233).

The International Consensus Statement recommends the use of IIFT as an ANCA screening test and both anti-PR3 and anti-MPO ELISAs to confirm positive IIFT results. The combination of these two test systems provides the highest specificity and sensitivity for the detection of small-vessel vasculitides.

ProductOrder number
Anti-PR3-hn-hr ELISA (IgG)EA 1201-2 G

Anti-Myeloperoxidase ELISA

Myeloperoxidase is the main target antigen of pANCA. However, since not all pANCA are positive in anti-MPO ELISA, an immunofluorescence test should always be performed in parallel to the anti-MPO ELISA. When the immunofluorescence results are positive, ambiguous or discrepant with respect to the clinical picture, the findings must always be confirmed and differentiated using ELISA based on defined target antigens e.g., Anti-MPO-ELISA or the EUROIMMUN ANCA Profile ELISA (with the antigens proteinase 3, myeloperoxidase, granulocyten elastase, cathepsin G, lysozyme, lactoferrin).

ProductOrder number
Anti-Myeloperoxidase ELISA (IgG)EA 1211 G

To top


Incubated EUROLINE MPO/PR3/GBM Profile
  • Determination of autoantibodies against antigens of neutrophil granulocytes and the glomerular basement membrane for the serological diagnosis of Wegener's granulomatosis, microscopic polyangiitis, rapid progressive glomerulonephritis, Goodpasture syndrome and other forms of vasculitis.
  • Membrane chips printed with individual lines of purified and biochemically characterised antigens. Each antigen is coated onto a separate membrance chip, providing optimal efficiency of antibody detection for each protein.
  • Serum dilution 1 : 101; conjugate class anti-human IgG, alkaline phosphatase-labelled.
  • The EUROLINE Profile allows the determination of 3 autoantibodies: antibodies against MPO, PR3 and GBM.
  • The test strips can be automatically incubated and evaluated using the EUROBlotMaster or EUROBlotOne systems and the EUROLineScan programme.

ProductOrder number